Breast Cancer Research and Treatment (2018) 167:605–606
https://doi.org/10.1007/s10549-017-4633-6

CORRECTION

Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer

Muhammad Asaduzzaman[1,5] · Stephanie Constantinou[1,6] · Haoxiang Min[1] · John Gallon[1] · Meng-Lay Lin[1] · Poonam Singh[2] · Selina Raguz[3] · Simak Ali[1] · Sami Shousha[2] · R. Charles Coombes[1] · Eric W.-F. Lam[1] · Yunhui Hu[4] · Ernesto Yagüe[1]

Published online: 5 January 2018

Correction to: Breast Cancer Res Treat (2017) 163:461–474
https://doi.org/10.1007/s10549-017-4202-z

In the original publication, Fig. 1 depicting the blot for EP300 in CAL51 cells (Fig. 1c) was unintentionally duplicated with that from MDA-MB-231 cells (Fig. 1d). The new figure given in this erratum depicts the correct EP300 blot in Fig. 1c.

The original article can be found online at https://doi.org/10.1007/s10549-017-4202-z.

✉ Yunhui Hu
417501784@qq.com

✉ Ernesto Yagüe
ernesto.yague@imperial.ac.uk

1 Division of Cancer, Imperial College Faculty of Medicine, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK

2 Centre for Pathology, Department of Medicine, Imperial College Faculty of Medicine, Charing Cross Hospital, Fulham Palace Rd, London W6 8RF, UK

3 Division of Clinical Sciences, Imperial College Faculty of Medicine, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK

4 The 3rd Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan Hu Xi Road, Ti Yuan Bei, He xi District, Tianjin 300060, People's Republic of China

5 Present Address: Department of Clinical Pharmacy and Pharmacology, University of Dhaka, Dhaka 1000, Bangladesh

6 Present Address: MRC Cancer Unit, Hutchison/MRC Research Centre, Cambridge CB2 0XZ, UK



Fig. 1 Experimental modulation of EP300 in cellular models. Expression of EP300 and E-cadherin was determined by immunoblot analyses. **a** EP300 was downregulated in breast cancer luminal MCF-7 cells by lentiviral expression of two different EP300 hairpins (MCF7-shEP300-1 and MCF7-shEP300-2). Cells expressing the empty pGIPZ vector (MCF7-shev) were used as control. **b** A genetic knock-out of EP300 (HCT-KOEP300) is available in colon carcinoma HCT116 cells. This cell line is hemizygous for the *EP300* locus and generates a C-terminus truncated EP300 protein [10]—note its lower molecular mass (tEP300, truncated EP300). Paclitaxel-resistant derivatives are indicated with the -TX name extension. **c**, **d** EP300 was upregulated in breast cancer basal-like CAL51 and MDA-MB-231 cells with an EP300 expression cassette in pcDNA3.1 (CAL-EP300 and MDA-EP300). In both cases, cells transfected with pcDNA3.1 were used as controls (CAL-ev and MDA-ev). Lamin B was used as a loading control. Representative pictures of three replicates are shown. Immunoblots were quantified and data are shown in the histograms as average ± SD of three blots. All statistical comparisons (*$P < 0.05$) versus control cells